Evidence map›Paper›PMID 33917201›Full record

ArticleCells2021

p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.

Ingvild Haaland, Sigrun M Hjelle, Håkon Reikvam, André Sulen, Anita Ryningen, Emmet McCormack, Øystein Bruserud, Bjørn Tore Gjertsen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. The p53 Isoforms as Potential Biomarkers in Different Cancer Entities.International journal of molecular sciences · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ingvild HaalandDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Sigrun M HjelleDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Håkon ReikvamDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.ORCID 0000-0001-5439-8411
André SulenDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Anita RyningenChemistry and Biomedical Laboratory Sciences, Department of Safety, Faculty of Engineering and Natural Sciences, Western Norway University of Applied Sciences, 5063 Bergen, Norway.
Emmet McCormackDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.ORCID 0000-0002-7621-4625
Øystein BruserudDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.
Bjørn Tore GjertsenDepartment of Clinical Science, University of Bergen, 5021 Bergen, Norway.ORCID 0000-0001-9358-9704
University of Bergen · NOHaukeland University Hospital · NOWestern Norway University of Applied Sciences · NO

Funding

Kreftforeningen 144345-2014Norges Forskningsråd 239837
6 · The paper itself

Abstract

p53 protein isoform expression has been found to correlate with prognosis and chemotherapy response in acute myeloid leukemia (AML). We aimed to investigate how p53 protein isoforms are modulated during epigenetic differentiation therapy in AML, and if p53 isoform expression could be a potential biomarker for predicting a response to this treatment. p53 full-length (FL), p53β and p53γ protein isoforms were analyzed by 1D and 2D gel immunoblots in AML cell lines, primary AML cells from untreated patients and AML cells from patients before and after treatment with valproic acid (VPA), all-

Indexed as

Epigenesis, GeneticAdultAgedAged, 80 and overBlast CrisisCell DifferentiationCell Line, TumorFemaleGene Expression Regulation, LeukemicHumansLeukemia, Myeloid, AcuteMaleMiddle AgedProtein IsoformsTumor Suppressor Protein p53Valproic AcidProtein IsoformsTumor Suppressor Protein p53Valproic Acidacute myeloid leukemiaall-trans retinoic aciddifferentiation therapyFrench–American–British (FAB) classificationp53 protein isoformsvalproic acid

Identifiers

PMID33917201
PMCPMC8068061
OpenAlexW3140913868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.